Core Viewpoint - The sales of Anjiahin® are expected to decline significantly by 2025 due to several factors, including medical insurance cost control and substantial price reductions initiated by the company in response to national healthcare policies [1] Group 1: Sales and Market Impact - The decline in Anjiahin® sales is primarily influenced by the reduction in patient usage resulting from medical insurance cost control measures [1] - Starting from the third quarter of 2025, Anjiahin® will undergo significant price cuts to align with the national healthcare bureau's initiatives, aiming to make the medication more accessible to patients [1] Group 2: Treatment Guidelines and Patient Care - The revised "Chinese Guidelines for Hemophilia Treatment (2025 Edition)" has redefined treatment approaches for coagulation disorders, shifting from traditional preventive treatment to regular replacement therapy and from on-demand treatment to temporary replacement therapy [1] - The medical community is emphasizing the importance of preventive treatment, and the company hopes that adult patients will receive similar protections as pediatric patients [1] - The company anticipates that the recombinant factor VIII will receive equal treatment as blood-derived factor VIII in the future [1]

Group 1 - The core viewpoint of the article highlights a significant decline in sales of the product Anjiaan® in 2025, attributed to several factors including medical insurance cost control leading to reduced patient usage [2] - The company has implemented a substantial price reduction for Anjiaan® starting from the third quarter of 2025 in response to the National Medical Insurance Administration's call, aiming to benefit patients and improve their survival conditions [2] - The revised "Guidelines for the Treatment of Hemophilia in China (2025 Edition)" has redefined treatment approaches for coagulation disorders, emphasizing the importance of preventive treatment and calling for better protection for adult patients similar to that of children [2]

Core Viewpoint - The company Shenzhou Cell indicates that the sales of its product Anjiah will decline significantly in 2025 due to several factors, including medical insurance cost control and substantial price reductions in response to national healthcare policies [1] Group 1: Sales Decline Factors - Medical insurance cost control has led to a decrease in patient usage [1] - Starting from the third quarter of 2025, Anjiah will undergo significant price reductions to align with national healthcare bureau initiatives [1] Group 2: Future Expectations - The company hopes that the price reduction of Anjiah will benefit patients, allowing them to access sufficient medication and improve their survival conditions [1] - The revised "Guidelines for the Treatment of Hemophilia in China (2025 Edition)" emphasizes the importance of preventive treatment and redefines treatment approaches for coagulation disorders [1] - The company anticipates that adult patients will receive better protection similar to that of pediatric patients and hopes that recombinant factor VIII will be treated equally to plasma-derived factor VIII [1]

Core Insights - Novo Nordisk announced the official launch of injectable pegylated recombinant factor VIII (brand name: Nuwiq®) in mainland China, marking it as the only long-acting recombinant factor VIII approved in the country [1] - Nuwiq® has been added to the new national medical insurance catalog, enhancing accessibility for patients with Hemophilia A and ushering them into a new treatment phase [1] Group 1: Product and Market Impact - Nuwiq® fills a significant gap in long-term treatment for Hemophilia A in China, which affects approximately 80%-85% of all hemophilia patients [1] - The product's launch is expected to improve medication accessibility for patients, who require lifelong treatment to avoid severe health risks [1] Group 2: Clinical Data and Efficacy - Since its approval in the U.S. in 2019, Nuwiq® has accumulated extensive efficacy and safety data for the prevention and treatment of bleeding globally [1] - In a multi-center trial (Pathfinder10) conducted among Chinese Hemophilia A patients, the median annualized bleeding rate (ABR) for those receiving preventive treatment with Nuwiq® was 0.00, with 69.4% of patients experiencing zero bleeding events and a 94.8% success rate in stopping bleeding [1]

Core Viewpoint - Novo Nordisk has officially launched the injectable product, Pegylated Coagulation Factor VIII (brand name: Nuwiq), in mainland China, marking it as the only approved long-acting recombinant factor VIII in the country, which has been included in the new national medical insurance catalog [1] Group 1: Product Launch and Market Impact - The launch of Nuwiq fills a significant gap in long-term treatment options for Hemophilia A in China, enhancing medication accessibility for patients and ushering them into a new treatment phase [1] - Hemophilia A, characterized by a deficiency of coagulation factor VIII, accounts for approximately 80%-85% of all hemophilia cases, necessitating lifelong treatment to prevent severe health consequences [1] Group 2: Clinical Data and Efficacy - Since its approval in the United States in 2019, Nuwiq has accumulated extensive efficacy and safety data for the prevention and treatment of bleeding globally [1] - In a multi-center trial (Pathfinder105) conducted among Chinese Hemophilia A patients, the median annualized bleeding rate (ABR) for those receiving preventive treatment with Nuwiq was 0.00, with a 69.4% rate of zero bleeding patients and a 94.8% success rate in stopping bleeding episodes [1]

诺和诺德全球高级副总裁兼大中国区总裁周霞萍表示："诺易特®上市并纳入医保，是诺和诺德深耕中 国罕见病领域的重要成果。从诺其®、诺易®到诺易特®，诺和诺德将持续为中国血友病患者提供优质 方案，逐步提高患者的药物可及性，不断完善患者服务体系，助力'健康中国2030'目标实现。" （文章来源：21世纪经济报道） 自2019年在美国获批上市以来，诺易特®在全球积累了丰富的预防和治疗出血的疗效和安全性数据。在 中国血友病A患者中进行的多中心试验Pathfinder105 结果显示，诺易特®接受预防治疗的患者中位年化 近日，全球领先的生物制药公司诺和诺德宣布，注射用培妥罗凝血素α（商品名：诺易特®）在中国大 陆正式上市。诺易特®是我国首个且目前唯一*获批的长效重组凝血因子Ⅷ，且已成功被新版国家医保 目录新增纳入。诺易特®在中国大陆市场的全面上市填补了血友病A长效治疗的空白，进一步提升了患 者用药的可及性，将中国血友病A患者带入全新治疗阶段。 出血率（ABR）为0.00，零出血患者比例高达69.4%，治疗出血的止血成功率为94.8%，为中国血友病A 患者提供高效便捷的治疗选择。 诺易特®适用于12岁及以上血友病A（先天性凝 ...

Core Viewpoint - Novo Nordisk has officially launched the long-acting recombinant coagulation factor VIII, Nuwiq, in mainland China, marking it as the first and only approved treatment for Hemophilia A in the country, which enhances patient accessibility to medication and introduces a new treatment phase for Hemophilia A patients in China [1][3]. Group 1: Product Launch and Market Impact - Nuwiq is now included in the new national medical insurance directory, significantly reducing the treatment burden for patients and addressing the issue of affordability for innovative drugs [4]. - The launch of Nuwiq fills a gap in long-term treatment options for Hemophilia A, which affects approximately 80%-85% of all hemophilia patients [3]. Group 2: Clinical Efficacy and Safety - Clinical trials, such as the Pathfinder105 study, demonstrated that patients receiving preventive treatment with Nuwiq had a median annualized bleeding rate (ABR) of 0.00, with 69.4% of patients experiencing zero bleeding events and a hemostatic success rate of 94.8% [3]. - Nuwiq extends the half-life of coagulation factor VIII to 19 hours, which is 1.6 times longer than standard formulations, allowing for a reduction of 50%-71% in intravenous injection frequency, thus improving treatment adherence [3]. Group 3: Future Commitment and Goals - Novo Nordisk aims to continue enhancing drug accessibility for Hemophilia patients in China and is committed to improving patient service systems to support the "Healthy China 2030" initiative [4].

Core Viewpoint - Pfizer's stock dropped over 1% following the death of a patient involved in a long-term study of its hemophilia drug, Hympavzi, which was approved in the U.S. last year for treating hemophilia A or B patients aged 12 and older [3][4]. Group 1: Patient Incident - A patient participating in the study died from a stroke and intracranial hemorrhage on December 14 [4]. - Pfizer is actively gathering information in collaboration with trial researchers and an independent external data monitoring committee to understand the complexities surrounding the incident [4]. - The company stated that, based on current understanding and overall clinical data collected so far, the death is not expected to impact the safety of patients receiving the treatment [4]. Group 2: Drug Background - Hympavzi is a long-acting coagulation factor therapy administered weekly, aimed at preventing or reducing bleeding in hemophilia patients [4]. - In addition to Hympavzi, gene therapies have emerged as another treatment option for hemophilia in recent years [4]. Group 3: Previous Developments - Pfizer previously developed a one-time gene therapy, Beqvez, for treating adults with moderate to severe hemophilia B, which was approved in the U.S. [5]. - However, due to high costs and weak demand, Pfizer announced earlier this year that it would cease global development and commercialization of its hemophilia gene therapy [5].

Core Insights - Pfizer reported a patient death during a long-term study of its hemophilia drug, Hympavzi, which led to a stock price drop of over 1% on December 23 [1] - The patient died from a stroke and intracerebral hemorrhage on December 14, as confirmed by the European Hemophilia Consortium [1] - Pfizer stated that it does not expect this incident to impact the safety of patients receiving the drug, based on current clinical data [1] Group 1 - The patient involved was part of a long-term study for Hympavzi, a long-acting clotting factor therapy approved in the U.S. for patients aged 12 and older with hemophilia A or B [1] - Hympavzi is administered weekly and aims to prevent or reduce bleeding by targeting clotting proteins [1] - Pfizer is actively gathering information in collaboration with trial researchers and an independent external data monitoring committee to understand the complexities surrounding the incident [1] Group 2 - Pfizer previously developed a one-time gene therapy, Beqvez, for treating moderate to severe hemophilia B in adults, which was approved in the U.S. [2] - However, due to high costs and weak demand, Pfizer announced the cessation of global development and commercialization of its hemophilia gene therapy earlier this year [2]

Core Insights - Novo Nordisk has submitted applications to the FDA for the approval of icodec insulin for the treatment of type 2 diabetes and Mim8 for the treatment of hemophilia A [1] Group 1: Icodec Insulin - Icodec insulin is a long-acting insulin formulation designed based on oral insulin OI338, with a half-life of 196 hours [2] - The design modifications include replacing an 18C fatty acid with a 20C fatty acid to enhance binding affinity to human serum albumin, and substituting Tyr with His at position 16 of the B chain to reduce affinity to human insulin receptors [2] - The initial BLA submission in April 2023 included indications for both type 1 and type 2 diabetes, but the FDA advisory committee found insufficient data for type 1 diabetes, leading to a narrowed indication for type 2 diabetes in the resubmission [2] Group 2: Mim8 - Mim8 is a bispecific antibody developed using Genmab's DuoBody technology, designed to mimic the action of coagulation factor VIIIa (FVIIIa) and bridge factors IXa (FIXa) and X (FX) [3] - It exhibits approximately 15 times the coagulation activity compared to emicizumab [3] - Hemophilia A, affecting around 80%-85% of the estimated 1.125 million hemophilia patients globally, is caused by a deficiency or defect in FVIII [3] Group 3: Hemophilia Treatment Landscape - There are currently 46 approved hemophilia drugs globally, with only 8 being non-factor therapies [4] - Among these, several drugs have been approved specifically for hemophilia A patients, including concizumab, valoctocogene roxaparvovec, emicizumab, marstacimab, and fitusiran [4]